Redeye comments on Cereno’s Q2 2022 report, and we judge that the company is making solid progress on all fronts. Cereno recruited the first patient to its phase II trial with CS1 in PAH in early July, setting the stage for communicating top-line data in Q1 2023E.

Länk till analysen